Extracorporeal Photopheresis
Summary
Extracorporeal photopheresis may be considered medically necessary to treat cardiac allograft rejection that is recurrent or refractory to standard immunosuppressive drug treatment, and to treat acute or chronic graft-versus-host disease that is refractory to medical therapy. It may also be considered medically necessary for late-stage (III or IV) cutaneous T-cell lymphoma and for early-stage (I or II) cutaneous T-cell lymphoma that is progressive and refractory to established nonsystemic therapies. Other solid organ rejection uses, graft-versus-host disease that is previously untreated or responding to established therapies, early-stage cutaneous T-cell lymphoma that is untreated or responsive to established nonsystemic therapies, autoimmune diseases, and all other indications are considered investigational.
Get alerts when payers change rules like this one
We check Blue Cross & Blue Shield of Mississippi and other payers every day and email you when a change matches your specialty and state.